Article Text

Download PDFPDF
Serum proteomic patterns for ovarian cancer monitoring
  1. J. Helleman*,
  2. D. Van Der Vlies*,
  3. M. P.H.M. Jansen*,
  4. T. M. Luider,
  5. M. E.L. Van Der Burg*,
  6. G. Stoter* and
  7. E. M.J.J. Berns*
  1. * Departments of Medical Oncology and
  2. Neurology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
  1. Address correspondence and reprint requests to: J.H. and D. van der V. contributed equally to this work.


We set out to discover ovarian cancer biomarkers useful for monitoring progression during and after chemotherapy and possibly for diagnosis. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry was used to create serum protein profiles of ovarian cancer patients before chemotherapy or at progression (n= 51) (trial initiated by the Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer trial) that were compared with those of healthy individuals (n= 31). In addition, sera profiles from ovarian cancer patients after chemotherapy (n= 12) were compared with those of ovarian cancer patients at progression (n= 24). One of the discovered biomarkers was identified and subsequently confirmed and validated using enzyme-linked immunosorbent assay (ELISA). Eight primary (sens = 94%, spec = 97%, P< 0.0001) and seven progression tumor biomarkers (sens = 91%, spec = 97%, P< 0.0001) were discovered. In addition, we discovered eight potential progression monitoring biomarkers (sens = 75%, spec = 83%, P= 0.0008) of which one, a biomarker of 11.7 kd, was further identified as serum amyloid A1. Independent validation (ELISA) showed an elevated expression of this protein at relapse in four of the seven ovarian cancer patients tested. Combining the eight newly discovered progression monitoring biomarkers with CA125 resulted in a clear increase of the sensitivity (91–100%). These biomarkers, in combination with for instance CA125, should be validated in large ovarian cancer and control groups. The resulting multimarker assay could be suitable for disease monitoring during and after therapy and might also be useful for ovarian cancer screening.

  • ovarian cancer
  • progression monitoring
  • serum protein profiling

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.